Overview

Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research study is to learn if Irbesartan is superior to placebo in reducing mortality and cardiovascular morbidity in subjects with heart failure with preserved systolic function. The safety of this treatment will also be studied.
Phase:
Phase 3
Details
Lead Sponsor:
Bristol-Myers Squibb
Collaborator:
Sanofi
Treatments:
Irbesartan